Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) disclosed on 27 October 2026 that it bought back 50,000 H-shares on the Hong Kong Stock Exchange the same day, paying a total of HKD 2.11 million. The shares were repurchased within a price range of HKD 41.70 to HKD 42.60, translating into a volume-weighted average cost of HKD 42.17 per share. All repurchased shares will be held as treasury stock.
The transaction trimmed RIBOLIFE-B’s issued share capital (excluding treasury shares) by 0.03%, from 169.51 million to 169.46 million shares. Treasury shares increased from 1.05 million to 1.10 million, while the company’s total issued shares remained unchanged at 170.55 million.
The buy-back forms part of the repurchase mandate approved by shareholders on 5 June 2026, which authorises the company to repurchase up to 17.06 million shares. Cumulative on-market repurchases under this mandate now stand at 1.10 million shares, equivalent to 0.64% of the company’s issued share capital at the mandate date, leaving headroom of roughly 15.96 million shares.
In line with Hong Kong listing regulations, RIBOLIFE-B is subject to a 30-day moratorium on new share issues or treasury share disposals, effective until 26 November 2026.
Comments